Maze Therapeutics reports Q1 EPS (45c), consensus (63c)

Reports Q1 revenue $20M, consensus $8.5M. License revenue was $20M for Q1. No license revenue was recognized for the quarter ended March 31, 2025. License revenue recognized in Q1 of 2026 reflects the achievement of a milestone pursuant to the exclusive license agreement with Shionogi & Co. for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup. Cash, cash equivalents and marketable securities were $362.9M as of March 31, compared to $360.0M as of December 31, 2025. Maze expects that its cash, cash equivalents and marketable securities as of March 31, together with the proceeds from the registered offering completed in April and a $20M milestone payment received from Shionogi & Co. in April, will fund operations into 2029 based on its current business plan.